In patients with chronic low back pain with comorbidities such as hypertension, diabetes, and cardiovascular disease, extended-release oxymorphone (Opana ER, Endo Pharmaceuticals) may be a safe and effective alternative, according to a study presented at the annual meeting of the American Academy of Pain Medicine, National Harbor, Md.
In patients with chronic low back pain (CLBP) with comorbidities such as hypertension, diabetes, and cardiovascular disease (CVD), extended-release oxymorphone (Opana ER, Endo Pharmaceuticals) may be a safe and effective alternative, according to a study presented at the annual meeting of the American Academy of Pain Medicine, National Harbor, Md.
“When the presence of hypertension, diabetes, or cardiovascular disease is unfavorable to the risk-benefit considerations of other treatment options, oxymorphone extended-release may be an appropriate alternative," said John Peniston, DO, lead author, Feasterville Family Health Care Center, Feasterville, Pa.
A total of 575 patients were included in this post-hoc, subpopulation analysis of 2 randomized trials comparing oxymorphone ER with placebo in opioid-experienced and opioid-naïve patients with CLBP. In all, 35.5% of patients were hypertensive, 11.3% diabetic, and 13.9% had CVD.
During the open-label titration period (≤1 month), opioid-naïve patients initiated treatment with oxymorphone ER (5 mg) every 12 hours; opioid-experienced patients began treatment at the dose calculated to be equivalent to the patient’s current opioid therapy based on established dose conversion tables. Patients were titrated in increments of 5 mg to 10 mg every 12 hours every 3 to 7 days to a stabilized dose at which pain intensity was ≤40 mm according to the 100-mm Visual Analog Scale (VAS) for 3 or more of 5 consecutive days.
During this titration period, the incidence of ≥1 adverse events was similar in populations with and without hypertension (69.1% vs 69.3%, respectively), diabetes (73.8% vs. 68.6%), and CVD (73.8% vs 68.5%). Serious adverse events occurred in similar proportions of patients with or without hypertension (4 vs 3, respectively), diabetes (4 vs 3), and CVD (3 vs 4).
Mean VAS pain intensity declined significantly compared with baseline in all patients, from 69.8 at screening to 20.7 at baseline. Similar baseline VAS pain ratings were seen in patients with and without hypertension (20.8 and 20.4, respectively), diabetes (20.5 and 25.5), and CVD (18.4 and 21.3).
During the 12-week double-blind treatment period, patients received either placebo or continued treatment with oxymorphone ER at their stabilized dose. Oxymorphone immediate-release (5 mg every 4 to 6 hours as needed) was permitted as rescue medication during the first 4 days of treatment after which the maximum allowed dose was 10 mg/d.
Adverse events were more common with oxymorphone ER compared with placebo (52.6% vs. 41.0%, respectively). Nausea, constipation, headache, diarrhea, vomiting, and dizziness were the most common. Serious adverse events occurred in 4 patients treated with oxymorphone ER and 3 treated with placebo.
Similar small increases in mean VAS pain intensity from baseline to final visit in the oxymorphone ER treatment group were seen in patients with and without hypertension (9.8 vs 9.6, respectively), diabetes (13.3 vs 9.2), and CVD (13.0 vs 9.2) during the treatment period. Similar substantial increases in VAS pain intensity from baseline to final visit in the placebo group were observed in patients with and without hypertension (27.9 vs 28.4, respectively), diabetes (26.6 vs 28.4), and CVD (30.3 vs 28.0).
This study was funded by Endo Pharmaceuticals Inc.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen